Arcellx

Yahoo Finance • 6 days ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the Col... Full story

Yahoo Finance • last year

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma -- -- The companies expand the scope of the... Full story

Yahoo Finance • last year

Kite and Arcellx Announce Expansion in Strategic Partnership

-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas -- -- Kite exercises option to Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma -- -- Arcellx to receive $200M equity investme... Full story

Yahoo Finance • 2 years ago

Gilead to co-develop Arcellx's multiple myeloma drug

Gilead Sciences Inc. said Friday that it will co-develop and co-commercialize Arcellx Inc.'s multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $10... Full story

Yahoo Finance • 2 years ago

‘The bear market rally has more room to run,’ Guggenheim Says. Here are 2 stocks to bet on

The October inflation numbers came out last week, and sparked solid gains in the markets. Investors were buoyed by better-than-expected price data when the Bureau of Labor Statistics’ Consumer Price Index came in at 7.7% annualized. This w... Full story